KIROMIC BIOPHARM(KRBP) - 2023 Q4 - Annual Report

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K For the transition period from to Commission File Number: 001-39169 Kiromic BioPharma, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4762913 (State or other juri ...